Seven years of follow up of trabecular bone score, bone mineral density, body composition and quality of life in adults with growth hormone deficiency treated with rhGH replacement in a single center

Miguel, Gonzalo Allo; Plá, Alicia Serraclara; Muñoz, Myriam Lorena Partida; Díaz-Guerra, Guillermo Martínez; Hawkins, Federico

doi:10.1177/2042018816643908

Cited by 20 publications

(10 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lumbar spine and femur BMD were recorded in the whole group of 147 GHD patients (age 35.1 years, 84 males/63 females, 43 cases of childhood onset GHD/104 cases of adult onset GHD) and increased significantly during a two-year period of treatment (14% and 7% increase, respectively) [36]. The second study on a group of 18 adult GHD patients (mean age, 37.39 ± 12.42 years) demonstrated that over a seven-year treatment time TBS remained at the baseline level (no statistically significant differences) whereas lumbar spine BMD increased (p = 0.01) [37].…”

Section: Disorders Of the Growth Hormone/insulin-like Growth Factor 1mentioning

confidence: 95%

Trabecular bone score (TBS) as a noninvasive and complementary tool for clinical diagnosis of bone structure in endocrine disorders

Halupczok-Żyła

Bolanowski

2019

Endokrynologia Polska

View full text Add to dashboard Cite

Trabecular bone score (TBS) index has recently been obtained as a result of textural greyscale analysis of DXA images. Because it enables the assessment of bone microarchitectural texture, TBS may be useful in evaluating bone quality. This study explores the current knowledge of the use of TBS in patients with endocrine disorders with co-occurring bone structure changes. Currently, the clinical importance TBS was verified in terms of disorders of the growth hormone/insulin-like growth factor 1 (GH/IGF-I) axis, glucocorticoid excess, thyroid and parathyroid disease, as well as in diabetes mellitus type 1 and 2. It has been clarified that patients suffering from various endocrinopathies are a group in which TBS should be used routinely because it correlates with clinical factors and may improve patient management in various endocrine disorders. (Endokrynol Pol 2019; 70 (4): 350-356)

show abstract

Section: Disorders Of the Growth Hormone/insulin-like Growth Factor 1mentioning

confidence: 95%

Trabecular bone score (TBS) as a noninvasive and complementary tool for clinical diagnosis of bone structure in endocrine disorders

Halupczok-Żyła

Bolanowski

2019

Endokrynologia Polska

View full text Add to dashboard Cite

show abstract

“…Прибавка МПК на фоне лечения наблюдается через 18-24 мес после начала лечения, составляет около 4-10%, более заметное увеличение отмечается в позвонках [114]. В проспективном исследовании с 18 пациентами с СТГ-дефицитом, получавшими лечение соматотропином в течение 7 лет, отмечено повышение МПК и сохранение показателей на фоне длительной терапии; однако, достоверного положительного влияния на микроархитектонику кости не выявлено [115]. В когорте из 230 взрослых пациентов с СТГ-дефицитом, получавших терапию соматропином, которых наблюдали в течение 15 лет, отмечено устойчивое повышение МПК в позвонках, более заметное среди мужчин, и стабилизация МПК в шейке бедра.…”

Section: метаболические эффекты заместительной терапииunclassified

Current aspects of diagnosis and treatment of adult GH-deficiency

Lutsenko¹,

Nagaeva²,

Belaya³

et al. 2019

Probl Endokrinol (Mosk)

View full text Add to dashboard Cite

Adult growth hormone (GH) deficiency (AGHD) is a condition characterized by alterations in body composition, lipid and carbohydrate metabolism, bone mineral density and poor quality of life; however, clinical presentations of AGHD are mostly non-specific. Untreated AGHD is associated with increased cardiovascular morbidity and mortality. Stimulation tests are used for the diagnosis: insulin tolerance test, glucagon stimulation test, growth-hormone releasing hormone and arginine stimulation test. Moreover, in 2017 FDA approved the use of macimorelin (oral GH secretagogue) for the diagnosis of AGHD. In childhood GH-deficiency, apolipoprotein A-IV, CFHR4 (complement factor H-related protein 4) and PBP (platelet basic protein) were identified as potential biomarkers of the disease, however, this was not investigated in AGHD. GH treatment starts from the minimal dose, which allows minimizing the adverse effects. According to published meta-analyses, AGHD treatment generally does not lead to increased risk of malignancy and recurrence of sellar neoplasms in adult patients. Published data on GH receptor polymorphism associations with treatment efficacy remains controversial. Development of long-acting GH formulations is a currect perspective for the increase of treatment compliance.

show abstract

“…A prospective study in 18 patients with GHD showed that seven years of GH treatment induced an increase in lumbar spine BMD, which stabilizes during long-term therapy. However, a significant positive effect on bone microarchitecture could not be demonstrated in these patients [ 21 ]. Furthermore, two recent meta-analyses have suggested that the beneficial effect of GH therapy on BMD in adults with GHD is mainly affected by gender, age, dose and treatment duration [ 22 , 23 ].…”

Section: Benefits Of Treatment With Growth Hormonementioning

confidence: 99%

Treatment with Growth Hormone for Adults with Growth Hormone Deficiency Syndrome: Benefits and Risks

Díez

Sangiao‐Alvarellos

Cordido

2018

IJMS

View full text Add to dashboard Cite

Pharmacological treatment of growth hormone deficiency (GHD) in adults began in clinical practice more than 20 years ago. Since then, a great volume of experience has been accumulated on its effects on the symptoms and biochemical alterations that characterize this hormonal deficiency. The effects on body composition, muscle mass and strength, exercise capacity, glucose and lipid profile, bone metabolism, and quality of life have been fully demonstrated. The advance of knowledge has also taken place in the biological and molecular aspects of the action of this hormone in patients who have completed longitudinal growth. In recent years, several epidemiological studies have reported interesting information about the long-term effects of GH replacement therapy in regard to the possible induction of neoplasms and the potential development of diabetes. In addition, GH hormone receptor polymorphism could potentially influence GH therapy. Long-acting GH are under development to create a more convenient GH dosing profile, while retaining the excellent safety, efficacy, and tolerability of daily GH. In this article we compile the most recent data of GH replacement therapy in adults, as well as the molecular aspects that may condition a different sensitivity to this treatment.

show abstract

Seven years of follow up of trabecular bone score, bone mineral density, body composition and quality of life in adults with growth hormone deficiency treated with rhGH replacement in a single center

Cited by 20 publications

References 37 publications

Trabecular bone score (TBS) as a noninvasive and complementary tool for clinical diagnosis of bone structure in endocrine disorders

Trabecular bone score (TBS) as a noninvasive and complementary tool for clinical diagnosis of bone structure in endocrine disorders

Current aspects of diagnosis and treatment of adult GH-deficiency

Treatment with Growth Hormone for Adults with Growth Hormone Deficiency Syndrome: Benefits and Risks

Contact Info

Product

Resources

About